Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Eicosanoids as mediators in ARDS]

H M Loick1, J L Theissen

  • 1Klinik und Poliklinik für Anästhesiologie, Westfälische Wilhelms-Universität Münster.

Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of transoesophageal echocardiographic Doppler across the aortic valve and the thermodilution technique for estimating cardiac output.

Anaesthesia·1999
Same author

High thoracic epidural anesthesia, but not clonidine, attenuates the perioperative stress response via sympatholysis and reduces the release of troponin T in patients undergoing coronary artery bypass grafting.

Anesthesia and analgesia·1999
Same author

Combining nonpharmacologic therapies for advanced heart failure: the Münster experience with the assist device-defibrillator combination.

The American journal of cardiology·1999
Same author

Milrinone modulates endotoxemia, systemic inflammation, and subsequent acute phase response after cardiopulmonary bypass (CPB).

Anesthesiology·1999
Same author

Assessment of cardiovascular volume status by transoesophageal echocardiography and dye dilution during cardiac surgery.

European journal of anaesthesiology·1999
Same author

Emergency versus elective/urgent left ventricular assist device implantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·1998

Eicosanoids, derived from fatty acids, play a key role in acute respiratory distress syndrome (ARDS) pathophysiology. Understanding their imbalanced effects offers potential therapeutic interventions.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Physiology

Background:

  • Eicosanoids are lipid mediators derived from arachidonic acid and other fatty acids via cyclooxygenase and lipoxygenase pathways.
  • Key eicosanoids include leukotrienes and prostanoids (prostaglandins and thromboxane A2).
  • Eicosanoid metabolism pathways also process other fatty acids, yielding different prostaglandin and leukotriene series (e.g., series 1, 3, and 5).

Purpose of the Study:

  • To elucidate the role of eicosanoids in the pathophysiological changes observed in acute respiratory distress syndrome (ARDS).
  • To highlight the complex and not fully understood involvement of eicosanoids in ARDS.
  • To explore the potential for therapeutic interventions targeting drug-induced eicosanoid imbalances.

Main Methods:

Related Experiment Videos

  • Review of existing literature on eicosanoid metabolism and their roles in physiological and pathophysiological processes.
  • Analysis of the opposing effects of various eicosanoids on key parameters like bronchoconstriction, pulmonary hypertension, edema, and platelet aggregation.
  • Identification of specific eicosanoids involved in inflammatory cell activation.

    • Main Results:

    • Eicosanoids contribute to ARDS pathophysiology through an imbalance of opposing mediator effects.
    • Thromboxane A2 and leukotrienes exacerbate bronchoconstriction and pulmonary hypertension, while prostacyclin (PGI2) reduces them.
    • Leukotrienes, particularly LTB4, worsen pulmonary edema, whereas PGI2 offers protection. Thromboxane A2, PGF2, and LTB4 promote platelet aggregation, countered by PGE1 and PGI2.
    • LTB4 and 5-HETE activate inflammatory cells.

    Conclusions:

    • Eicosanoids are critical mediators in ARDS, with their imbalance significantly impacting disease progression.
    • Specific eicosanoids like thromboxane A2, leukotrienes, and prostacyclin have distinct and often opposing roles in ARDS.
    • Targeting eicosanoid pathways, particularly drug-induced imbalances, presents a promising avenue for therapeutic strategies in ARDS treatment.